This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 31 open trials.
In 131 locations
What is a Clinical Trial?
There are currently 31 open trials
- Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma (IDRIS)
- Effects of an exercise programme on smouldering myeloma and MGUS
- Selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma patients (MUK twelve)
- Tanezumab for bone pain in myeloma
- Donor lymphocyte infusion after stem cell transplant in myeloma (ProT4).
- CC-92480 in combination with dexamethasone in relapsed and refractory multiple myeloma
- GMI-1271 with standard of care for the treatment of multiple myeloma
- Post authorisation study of Pomalidomide (Imnovid)
- GSK2857916 in patients who have failed prior treatment with an anti-CD38 antibody (DREAMM 2)
- MGUS research study
- AZD4573 in relapsed or refractory myeloma
- Daratumumab vs. monitoring in high risk smouldering myeloma
- Selinexor for relapsed and refractory myeloma (BOSTON)
- RO6870810 monotherapy and combination for relapsed and refractory myeloma patients
- Ixazomib, pomalidomide and dexamethasone for relapsed and/or refractory myeloma patients
- Targeted radiotherapy for myeloma
- Observational study of presentation, treatment and outcomes in myeloma patients (INSIGHT-MM)
- Observational evaluation of myeloma patients (PREAMBLE)
- Image guided theranostics in myeloma (iTIMM)
- MUK nine b: OPTIMUM
- CAR-T cell therapy for relapsed and/or refractory myeloma (APRIL)
- Melflufen and dexamethasone in myleoma patients refractory to lenalidomide (OCEAN trial)
- CC-220 monotherapy and combination for relapsed and refractory myeloma patients
- MUK eleven (Reolysin trial)
- Myeloma XII (ACCoRd)
- Ixazomib and dexamethasone for relapsed or refractory AL amyloidosis patients
- MUK seven
- MUK eight
- Carfilzomib for newly diagnosed patients prior to stem cell transplant (CARDAMON trial)
- Bendamustine combination for newly diagnosed myeloma patients with kidney impairment (OPTIMAL trial)
- GSK525762 trial
Trial Title:
Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma (IDRIS)
Treatments:
Lenalidomide (Revlimid®)
Dexamethasone
Radiotherapy
Myeloma stage:
Bone Plasmacytoma
Trial phase:
III
Summary:
The aim of this trial is to determine whether taking lenalidomide and dexamethasone after radiotherapy is more effective at treating high risk solitary bone plasmacytoma than radiotherapy alone.
Locations:
Royal United Hospital, Bath;
Blackpool Victoria Hospital, Blackpool;
University Hospital of Wales, Cardiff;
Velindre Cancer Centre, Cardiff;
The Beatson Institute, Glasgow;
St James' Hospital, Leeds;
University College Hospital, London;
The Christie Hospital, Manchester;
Freeman Hospital, Newcastle;
Mount Vernon Cancer Centre, Northwood;
Royal Preston Hospital, Preston;
Salisbury District Hospital, Salisbury;
Southampton General Hospital, Southampton
Who can enter the study?:
Patients with newly diagnosed solitary bone plasmacytoma.
What's involved?:
Patients are randomised to receive either lenalidomide and dexamethasone or no treatment after receiving radiotherapy to treat the solitary bone plasmacytoma.
Patients assigned to the treatment leg of the trial will receive lenalidomide on days 1-21 and dexamethasone on days 1, 8, 15 & 22 for up to 9 cycles.
Patients maybe required to attend outpatient clinics for regular check-ups and tests.
Clinical Information
(for Medical Professionals):
The purpose of the phase III trial is to establish whether adjuvant therapy with lenalidomide and dexamethasone after radiotherapy can improve progression free survival in patients with high risk solitary bone plasmacytoma compared with radiotherapy only.
The investigators hope to demonstrate that adjuvant therapy with lenalidomide and dexamethasone prevents the development of multiple myeloma in patients with high risk solitary bone plasmacytoma.
For further information, click here.
Find out more: